Published: July 05, 2011

Research and Markets: Key Companies: HIV - Companies Co-operate and Co-formulate to Stay Competitive in a Tight HIV Market

Share This Story

DUBLIN - (BUSINESS WIRE) - Research and Markets (http://www.researchandmarkets.com/research/8e2e1a/key_companies_hiv) has announced the addition of the "Key Companies: HIV - Companies Co-operate and Co-formulate to Stay Competitive in a Tight HIV Market" report to their offering.

HIV across the seven major markets is largely dominated by two companies: Gilead Sciences and ViiV Healthcare. The growing dominance of convenient one-pill once-daily regimens will increasingly pressure companies to collaborate and co-formulate their marketed and/or pipeline HIV drugs into fixed dose combinations (FDCs) to remain successful in a tight HIV market.

Features and benefits

In-depth discussion of portfolios and strategies of key HIV companies.
Discussion of future strategic opportunities to achieve success in a crowded HIV market.
Review of corporate strategies in HIV.

Highlights

With Gilead and ViiV Healthcare clearly dominating the HIV market, the remaining companies active in the field have much smaller HIV portfolios. An emerging HIV treatment trend towards nuc-sparing regimens offers opportunities for smaller players to form new vertical collaborations and to diversify the HIV field.
With its blockbuster products Truvada (tenofovir disoproxil fumarate/emtricitabine) and Atripla (tenofovir disoproxil fumarate/emtricitabine/efavirenz), Gilead Sciences is the current HIV market leader in the seven major markets. Its strong late-stage pipeline will help Gilead to defend this position in the short- to mid-term future.
ViiV Healthcare's currently marketed HIV portfolio is diverse but includes several older drugs. However, of all companies involved in the HIV field, ViiV has by far the richest and most diverse HIV pipeline, offering plenty of opportunity to challenge Gilead's current position as HIV market leader in the mid-to long-term future.

Your key questions answered

Learn about the key HIV companies active in the seven major markets and their portfolios of marketed and pipeline HIV drugs.
Recognize trends in HIV drug development and learn how companies can respond to future opportunities and challenges in the field.
Understand corporate strategies for the life-cycle management of HIV drugs in the seven major markets.

Key Topics Covered:

Executive Summary

Strategic scoping and focus
Datamonitor key findings
Related reports

COMPANY STRATEGIES

Strategic overview
Trends in corporate strategy
Recent strategic partnerships/deals

GILEAD SCIENCES

Corporate strategy
HIV portfolio assessment
SWOT analysis for Gilead's HIV portfolio

VIIV HEALTHCARE

Corporate strategy
HIV portfolio assessment
SWOT analysis for ViiV Healthcare's HIV portfolio

PORTFOLIO REVIEW OF OTHER LEADING HIV COMPANIES

Companies are looking to the market leaders to co-formulate their novel HIV candidates
Tibotec/Johnson & Johnson: US approval of Edurant further strengthens position in the HIV market
Bristol-Myers Squibb: Sustiva's patent expiry and a slim HIV pipeline will weaken HIV franchise
Merck & Co: setbacks in 2010 threaten competitiveness in the HIV market
Abbott: HIV position set to decline following Norvir's patent expiry in 2013/
Boehringer Ingelheim: strong reliance on Viramune and Aptivus as key setback for future growth in HIV
Roche: suspended HIV research in

For more information visit http://www.researchandmarkets.com/research/8e2e1a/key_companies_hiv

Source: Datamonitor